Transgenic Research

, Volume 19, Issue 6, pp 1109–1117 | Cite as

Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell xenografts

  • Kazuhito Izukuri
  • Kenji Suzuki
  • Nobuyuki Yajima
  • Shigeyuki Ozawa
  • Shin Ito
  • Eiro Kubota
  • Ryu-Ichiro Hata
Original Paper

Abstract

We reported previously that the forced expression of the chemokine BRAK, also called CXCL14 in head and neck squamous cell carcinoma (HNSCC) cells decreased the rate of tumor formation and size of tumor xenografts compared with mock-vector treated cells in athymic nude mice or in severe combined immunodeficiency mice. This suppression occurred even though the growth rates of these cells were the same under in vitro culture conditions, suggesting that a high expression level of the gene in tumor cells is important for the suppression of tumor establishment in vivo. The aim of this study was to determine whether CXCL14/BRAK transgenic mice show resistance to tumor cell xenografts or not. CXCL14/BRAK cDNA was introduced into male C57BL/6 J pronuclei, and 10 founder transgenic mice (Tg) were obtained. Two lines of mice expressed over 10 times higher CXCL14/BRAK protein levels (14 and 11 ng/ml plasma, respectively) than normal blood level (0.9 ng/ml plasma), without apparent abnormality. The sizes of Lewis lung carcinoma and B16 melanoma cell xenografts in Tg mice were significantly smaller than those in control wild-type mice, indicating that CXCL14/BRAK, first found as a suppressor of tumor progression of HNSCC, also suppresses the progression of a carcinoma of other tissue origin. Immunohistochemical studies showed that invasion of blood vessels into tumors was suppressed in tumor xenografts of CXCL14/BRAK Tg mice. These results indicate that CXCL14/BRAK suppressed tumor cell xenografts by functioning paracrine or endocrine fashion and that CXCL14/BRAK is a very promising molecular target for tumor suppression without side effects.

Keywords

Chemokine CXCL14/BRAK Tumor suppression Lewis lung carcinoma cells Transgenic mouse Tumor therapy 

Notes

Acknowledgments

We appreciate Ms. Etsuko Shimada for preparation of reference list. This work was supported in part by a Grant-in Aid from the High-Tech Research Center Project of the Ministry of Education, Culture, Sports, Science and Technology of Japan and by a Grant-in Aid for Scientific Research from Japan Society for Promotion of Science.

References

  1. Akhurst RJ (2002) TGF-β antagonists: why suppress a tumor suppressor? J Clin Invest 109:1533–1536PubMedGoogle Scholar
  2. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6:17–32CrossRefPubMedGoogle Scholar
  3. Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L, Ostman A (2009) CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 106:3414–3419CrossRefPubMedGoogle Scholar
  4. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68:1–8PubMedGoogle Scholar
  5. Benatti P, Basile V, Merico D, Fantoni LI, Tagliafico E, Imbriano C (2008) A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional response. Nucleic Acids Res 36:1415–1428CrossRefPubMedGoogle Scholar
  6. Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46–54CrossRefPubMedGoogle Scholar
  7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232–239CrossRefPubMedGoogle Scholar
  8. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nature Med 14:518–527CrossRefPubMedGoogle Scholar
  9. Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK, Clayman GL (2000) In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156:1937–1950PubMedGoogle Scholar
  10. Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH (1980) Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci USA 77:7380–7384CrossRefPubMedGoogle Scholar
  11. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMedGoogle Scholar
  12. Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson K II, Azam M, Hou YH (1999) Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun 255:703–706CrossRefPubMedGoogle Scholar
  13. Izukuri K, Ito S, Nozaki N, Yajima N, Iwamiya M, Kawahara S, Suzuki K, Kubota E, Hata R (2010) Determination of serum BRAK/CXCL14 level in healthy volunteers. LabMedicine (in press)Google Scholar
  14. Kakinuma T, Hwang ST (2006) Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79:639–651CrossRefPubMedGoogle Scholar
  15. Krieg C, Boyman O (2009) The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin Cancer Biol 19:76–83CrossRefPubMedGoogle Scholar
  16. Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B (2001) Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med 194:855–861CrossRefPubMedGoogle Scholar
  17. Meuter S, Moser B (2008) Constitutive expression of CXCL14 in healthy human and murine epithelial tissues. Cytokine 44:248–255CrossRefPubMedGoogle Scholar
  18. Nara N, Nakayama Y, Okamoto S, Tamura H, Kiyono M, Muraoka M, Tanaka K, Taya C, Shitara H, Ishii R, Yonekawa H, Minokoshi Y, Hara T (2007) Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J Biol Chem 282:30794–30803CrossRefPubMedGoogle Scholar
  19. Nishimura G, Yanoma S, Satake K, Ikeda Y, Taguchi T, Nakamura Y, Hirose F, Tsukuda M (2000) An experimental model of tumor dormancy therapy for advanced head and neck carcinoma. Jpn J Cancer Res 91:1199–1203PubMedGoogle Scholar
  20. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193–199CrossRefPubMedGoogle Scholar
  21. Ozawa S, Kato Y, Komori R, Maehata Y, Kubota E, Hata R (2006) BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun 348:406–412CrossRefPubMedGoogle Scholar
  22. Ozawa S, Kato Y, Ito S, Komori R, Shiiki N, Tsukinoki K, Ozono S, Maehata Y, Taguchi T, Imagawa-Ishiguro Y, Tsukuda M, Kubota E, Hata RI (2009a) Restoration of BRAK/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer Sci 100:2202–2209CrossRefPubMedGoogle Scholar
  23. Ozawa S, Kato Y, Kubota E, Hata R (2009b) BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse. Biomed Res 30:315–318CrossRefPubMedGoogle Scholar
  24. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231CrossRefPubMedGoogle Scholar
  25. Pelicano H, Lu W, Zhou Y, Zhang W, Chen Z, Hu Y, Huang P (2009) Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res 69:2375–2383CrossRefPubMedGoogle Scholar
  26. Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. Cancer Lett 256:137–165CrossRefPubMedGoogle Scholar
  27. Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132–143CrossRefPubMedGoogle Scholar
  28. Sato K, Ozawa S, Izukuri K, Kato Y, Hata R (2010) Expression of tumor-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro. Cell Biol Int (in press).Google Scholar
  29. Schaerli P, Willimann K, Ebert LM, Walz A, Moser B (2005) Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 23:331–342CrossRefPubMedGoogle Scholar
  30. Schwarze SR, Luo J, Isaacs WB, Jarrard DF (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64:67–74CrossRefPubMedGoogle Scholar
  31. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, Ioannides CG, Efferson CL, El-Naggar AK, Roberts D, Clayman GL, Frederick MJ (2004) CXCL14/BRAK is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 64:8262–8270CrossRefPubMedGoogle Scholar
  32. Sidransky D (2002) Emerging molecular markers of cancer. Nat Rev Cancer 2:210–219CrossRefPubMedGoogle Scholar
  33. Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K, Hromas R (2006) The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol 34:1101–1105CrossRefPubMedGoogle Scholar
  34. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S-Y, Roczniak S, Shanafel AB (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348–27357CrossRefPubMedGoogle Scholar
  35. Suzuki K, Oida T, Hamada H, Hitotsumatsu O, Watanabe M, Hibi T, Yamamoto H, Kubota E, Kaminogawa S, Ishikawa H (2000) Gut cryptopatches: Direct evidence of extrathymic anatomical sites for intestinal T lymphopoiesis. Immunity 13:691–702CrossRefPubMedGoogle Scholar
  36. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532CrossRefPubMedGoogle Scholar
  37. Wang JM, Deng X, Gong W, Su S (1998) Chemokines and their role in tumor growth and metastasis. J Immunol Methods 220:1–17CrossRefPubMedGoogle Scholar
  38. Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Buchler MW, Friess H (2008) CXCL14 expression and potential function in pancreatic cancer. Cancer Lett 259:209–217CrossRefPubMedGoogle Scholar
  39. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 84:9233–9237CrossRefPubMedGoogle Scholar
  40. Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:243CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Kazuhito Izukuri
    • 1
  • Kenji Suzuki
    • 2
  • Nobuyuki Yajima
    • 1
  • Shigeyuki Ozawa
    • 2
  • Shin Ito
    • 1
  • Eiro Kubota
    • 2
  • Ryu-Ichiro Hata
    • 1
  1. 1.Oral Health Science Research Center/Department of Biochemistry and Molecular BiologyKanagawa Dental CollegeYokosukaJapan
  2. 2.Oral Health Science Research Center/Department of Oral and Maxillofacial SurgeryKanagawa Dental CollegeYokosukaJapan

Personalised recommendations